In a groundbreaking development poised to redefine the treatment landscape for locally advanced pancreatic cancer (LAPC), a new clinical trial has commenced that combines the cutting-edge bispecific antibody Ivonescimab with targeted stereotactic body radiotherapy (SBRT) and chemotherapy. This pioneering study addresses one of the most lethal malignancies—pancreatic ductal adenocarcinoma (PDAC)—known for its aggressive nature and limited therapeutic avenues, resulting in persistently high mortality rates worldwide.
The therapeutic paradigm shift explored in this trial capitalizes on the transformative potential of radiotherapy to convert PDAC tumors from immunologically “cold”—meaning unresponsive to immune attacks—to “hot,” thereby sensitizing them to immunotherapy. The immunogenic conversion fundamentally enhances the tumor’s susceptibility to immune checkpoint inhibitors, specifically anti-programmed cell death protein 1 (PD-1) targeted therapy. This strategic synergy aims to amplify the immune system’s ability to recognize and eradicate tumor cells, which traditionally evade detection in this cancer subtype.
Ivonescimab represents a new frontier in immunotherapy as a bispecific antibody adept at simultaneously targeting PD-1 and vascular endothelial growth factor (VEGF). By inhibiting VEGF, Ivonescimab not only disrupts tumor angiogenesis—a vital process for tumor growth and metastasis—but also modifications the pancreatic cancer microenvironment. VEGF blockade remodels this typically immunosuppressive environment into one that permits immune effector cells to infiltrate and attack the malignancy more effectively when combined with PD-1 inhibition.
The clinical trial, registered under NCT06844422, is designed as a single-arm, Phase Ib/II study, involving 37 patients diagnosed with LAPC. The Phase Ib segment primarily focuses on establishing the maximum tolerated dose (MTD) and identifying any dose-limiting toxicities (DLTs) of Ivonescimab. Employing a classical 3+3 dose-escalation design over four weeks, researchers meticulously titrate the dosage to define a recommended Phase II dose (RP2D), ensuring maximum efficacy blended with manageable safety profiles.
Transitioning into Phase II, the trial’s endpoint sharpens its focus on progression-free survival (PFS), a critical metric indicative of therapeutic benefit in this context. Patients receive the RP2D of Ivonescimab in conjunction with precise SBRT administration—a regimen delivering radiation doses ranging between 25 to 50 Gy over five fractions within two weeks—followed by tailored cycles of modified FOLFIRINOX chemotherapy. This chemotherapy combination, consisting of oxaliplatin, irinotecan, leucovorin, and fluorouracil, remains a cornerstone therapy for pancreatic cancer and is leveraged here to maximize cytotoxic effects synergistically with Ivonescimab and radiation.
A notable aspect of the study design is its emphasis on maintenance therapy. Patients who tolerate the combination regimen can continue with Ivonescimab monotherapy for up to 12 months or until disease progression or intolerable toxicity arises. This approach aims to sustain immune pressure on the tumor, potentially prolonging remission and delaying resistance.
The rationale underlying this multifaceted treatment strategy resides in recent translational research revealing that PDAC’s notoriously hostile tumor microenvironment attenuates the efficacy of single-modality immunotherapies. By strategically combining SBRT, chemotherapy, and dual blockade of PD-1 and VEGF pathways, the trial hopes to surmount the barriers posed by the dense stromal environment and immunosuppressive signals prevalent in PDAC.
Previous preclinical and clinical studies have hinted at the potential of anti-VEGF therapies to normalize tumor vasculature, decrease hypoxia, and reduce regulatory T-cell populations, collectively fostering a milieu more amenable to immune attack. Similarly, the use of stereotactic body radiotherapy offers localized high-dose radiation capable of releasing tumor antigens and upregulating immunogenic markers, further enhancing systemic anti-tumor immune responses.
Safety remains a paramount concern in this vulnerable patient population, and the Phase Ib segment’s structured dose-escalation ensures rigorous monitoring of adverse events. Dose-limiting toxicities, if observed, will inform dose adjustments to balance maximal therapeutic efficacy with patient safety—a critical consideration given the combinatorial therapy’s intensity.
The implications of this trial extend beyond individual patient outcomes. Should the therapy demonstrate a significant extension in progression-free survival or overall survival, it could reshape first-line treatment protocols for LAPC, a disease for which curative options remain circumscribed. Moreover, the study’s findings can catalyze further research into bispecific antibody therapies that simultaneously target multiple axes of tumor progression and immune evasion.
This trial also underscores the mounting significance of precision oncology, wherein treatments are no longer one-size-fits-all but intricately tailored based on the tumor’s immunobiological characteristics and microenvironmental context. The integration of advanced imaging, cytological analyses, and molecular profiling before enrollment exemplifies the meticulous patient selection aimed at optimizing therapeutic responsiveness.
The investigators anticipate that success in combining Ivonescimab with guided SBRT and chemotherapy could establish a new standard of care, mitigating the high morbidity associated with pancreatic cancer. Furthermore, the exploration of immune checkpoint and VEGF co-inhibition may open therapeutic avenues for other solid tumors marked by similar immunosuppressive microenvironments.
As the trial progresses, its rigorous methodology and innovative approach will contribute invaluable insights into the treatment resistance mechanisms intrinsic to pancreatic cancer. This knowledge will not only assist oncologists in clinical decision-making but may also drive the development of next-generation immunotherapeutic agents.
Early data dissemination from this study could also invigorate the oncology community’s efforts toward combinatorial immunotherapy regimens, highlighting how traditional treatments, like radiotherapy and chemotherapy, can synergistically complement immunomodulatory drugs. Such multidisciplinary approaches reflect the evolving complexity and sophistication in cancer management strategies.
In conclusion, this trial represents a bold and innovative stride against a formidable adversary in pancreatic cancer. By harnessing Ivonescimab’s dual-targeting capabilities alongside precise radiotherapy and chemotherapy, researchers aspire to tip the balance in favor of durable remission and improved quality of life for patients facing this daunting diagnosis. The oncology field awaits the results eagerly, which promise to be a pivotal chapter in the ongoing battle against PDAC.
Subject of Research: The study investigates the efficacy and safety of Ivonescimab, a bispecific antibody targeting PD-1 and VEGF, combined with stereotactic body radiotherapy (SBRT) and chemotherapy in patients with locally advanced pancreatic cancer (LAPC).
Article Title: Study protocol for a single-arm phase Ib/II trial of Ivonescimab combined with adapted guided stereotactic body radiotherapy and chemotherapy in patients with locally advanced pancreatic cancer.
Article References:
Tang, Z., Shi, F., Zhu, K. et al. Study protocol for a single-arm phase Ib/II trial of Ivonescimab combined with adapted guided stereotactic body radiotherapy and chemotherapy in patients with locally advanced pancreatic cancer. BMC Cancer 25, 1581 (2025). https://doi.org/10.1186/s12885-025-14944-w
Image Credits: Scienmag.com
DOI: https://doi.org/10.1186/s12885-025-14944-w
